Literature DB >> 30803447

Correction to: Efficacy of canakinumab as first-line biologic agent in adult-onset Still's disease.

Giulio Cavalli1,2,3, Alessandro Tomelleri4,5, Giacomo De Luca4,5, Corrado Campochiaro4, Charles A Dinarello6,7, Elena Baldissera4, Lorenzo Dagna4,5.   

Abstract

Following publication of the original article [1], the authors reported an error in the spelling of Lorenzo Dagna's name.

Entities:  

Year:  2019        PMID： 30803447      PMCID： PMC6388469          DOI： 10.1186/s13075-019-1850-x

Source DB:  PubMed          Journal:  Arthritis Res Ther        ISSN： 1478-6354            Impact factor:   5.156


Correction to: Arthritis Res Ther https://doi.org/10.1186/s13075-019-1843-9 Following publication of the original article [1], the authors reported an error in the spelling of Lorenzo Dagna’s name. The authors apologise for the error. Incorrect spelling: Loreno Dagna Correct spelling: Lorenzo Dagna The original article [1] has been updated.
  1 in total

1.  Efficacy of canakinumab as first-line biologic agent in adult-onset Still's disease.

Authors:  Giulio Cavalli; Alessandro Tomelleri; Giacomo De Luca; Corrado Campochiaro; Charles A Dinarello; Elena Baldissera; Lorenzo Dagna
Journal:  Arthritis Res Ther       Date:  2019-02-13       Impact factor: 5.156
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.